Surgical Oncology 2021 | Webinar | | Allied Conferences | Meetings

Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences

Theme

Pioneering the advancements in Surgical Oncology and Cancer Science

- Surgical Oncology 2021

Scientific Sessions/Tracks

Track 1: Glioblastoma Multiforme

New developments and significant advances have been made in the treatment of GBM. However, despite progress, recurrence is often inevitable and patient survival remains low. A variety of factors, including tumor complexity, the presence of the blood-brain barrier (BBB), and the presence of GBM cancer stem cells, complicate the identification of effective treatment options and require existing therapeutic approaches to be improved in cancer cells. And the research will yield new therapies to improve treatment strategies for GBM.

Sub Tracks:

· Tumor-derived small extracellular vesicles.

· Rindopepimut.

· Gene signature in Glioblastoma.

· Harnessing nanomedicine.

· Drug administration.

Related Conferences:

Surgical oncology Conference on Musical Research | Surgical oncology Conference on Surgical Gastroenterology and Surgical Oncology | Surgical oncology Conference on Advanced General and Pediatric Surgical Oncology | Cancer Conference on Trends in General and Pediatric Surgical Oncology | Cancer Conference on Cancer Research and Therapy | Cancer Conference on Advancements in Cancer Detection and Radiology Research | Cancer Science Conference on Oncogenesis and Cancer Research | Medical Oncology Conference on Oncology Nursing, Integrative Care and Pain Management | Medical Oncology Conference on Cancer Pathology Research | Tumor Conference on Applied Immunology and Oncology | Tumor Conference on Male Breast Cancer | Radiation Oncology Conference on Radiography and Radiotherapy | Radiation Oncology Conference on Radiotherapy in Cancer | Chemotherapy Conference on Nuclear Medicine, Imaging and Radiotherapy | Chemotherapy Conference on Intraoperative Radiotherapy | Carcinoma Conference on Cancer Immunotherapy and Radiotherapy

Related Associations and Societies:

Related Journals:

Track 2: Hepatocellular Carcinoma

Over the decades, advances in diagnosis, imaging, interventions, surgery, transplantation, and anticancer therapy have improved survival for patients with hepatocellular carcinoma. However, the overall long-term prognosis for hepatocellular carcinoma patients remains poor. Therefore, there is an urgent need to understand the biology of carcinogenesis, progression, metastasis, recurrence, and resistance to cancer therapies to develop new preventive/therapeutic approaches for hepatocellular carcinoma. Recently, in addition to curative treatments such as transplantation, resection, and ablation, tyrosine kinase inhibitors, PD-1 inhibitors, and their combinations have improved progression-free survival and overall survival in patients with unresectable advanced hepatocellular carcinoma. The period has been extended. In addition, antifibrotic, antiviral, and anti-inflammatory agents have been shown to reduce the risk of fibrosis progression and, accordingly, the risk of developing hepatocellular carcinoma.

Sub Tracks:

· Trans-arterial chemoembolization.

· Prognostic Markers.

· Drug Therapy Targeting.

· Clinical trials in Hepatocellular Carcinoma

Related Conferences:

Surgical oncology Conference on General and Pediatric Surgical Oncology | Surgical oncology Conference on Clinical Oncology and Pharmacology | Surgical oncology Conference on Trends in General and Pediatric Surgical Oncology| Surgical oncology Conference on Surgical Oncology | Surgical oncology Conference on Research Trends in General and Pediatric Surgical Oncology | Surgical oncology Conference on Labour Economics and Industrial Relations | Cancer Conference on Trends in General and Pediatric Surgical Oncology | Cancer Conference on Cancer Research and Therapy | Cancer Conference on Advancements in Cancer Detection and Radiology Research | Cancer Science Conference on Advanced Cancer Detection and Radiology Research | Cancer Science Conference on Cancer Research and Molecular Medicine | Medical oncology Conference on Medical Oncology and Molecular Medicine | Medical oncology Conference on Biology and Medicine of Breast Cancer | Radiation oncology Conference on Radiography and Radiotherapy | Medical oncology Conference on Diagnostic Imaging and Radiotherapy

Related Associations and Societies:

European Journal of Surgical Oncology | International Society of Geriatric Oncology | Annals of Surgical Oncology | American Association for Cancer Research | Association of Cancer With AIDS-Related Immunosuppression | Ovarian Cancer Support Organizations | German Cancer Research Centre | Comparison of Cancer Burden and Non-profit Organization | Integrative Cancer Science and Therapeutics | Japanese Society of Medical Oncology | Medical Oncology Group of Australia | Getting External Beam Radiation Therapy | The Israeli Society for Clinical and Radiation Oncology | Association of frailty and chemotherapy | The Association of Chemotherapy and Radiotherapy

Related Journals:

Journal of Cancer Science and Treatment | International Journal of Cancer Science and Therapy | ARC Journal of Cancer Science | Journal of Surgical Oncology | International Journal of Surgical Oncology | Journal of Surgical Oncology and Clinical Research | International Journal of Cancer and Oncology | World Journal of Surgical Oncology | Journal of Cancer Science and Research Open Access | Journal of Cancer Science and Clinical Oncology

Track 3: Myelodysplastic Syndrome

Currently approved treatments for MDS include those aimed at reducing the transfusion burden and improving anemia in low-risk diseases (recombinant erythropoietin, lenalidomide, and laspatercept) and those for prolonging survival in high-risk MDS. hypomethylating agent (HMA). However, these are not curative treatments, so allogeneic stem cell transplantation remains the only possible treatment. Patients eligible for clinical trials may benefit from investigational drugs. Treatment should be aimed at maintaining or improving health-related quality of life. This special issue outlines the unmet needs of patients with MDS and is designed to provide readers with a broader understanding of emerging biological insights integrated into current and future Surgical Oncology treatment options and their outcomes.

Sub Tracks:

· Single-lineage dysplasia.

· Excess blasts.

· Multilineage dysplasia.

· Chromosome abnormality.

Related Conferences:

Surgical oncology Conference on General Surgical Oncology and Surgery Types | Surgical oncology Conference on Trends in General and Pediatric Surgical Oncology | Surgical oncology Conference on Advancements in General Surgical Oncology | Cancer Conference on Research Trends in General and Pediatric Surgical Oncology | Cancer Conference on Current Trends in General Surgical Oncology and Surgery Types | Cancer Science Conference on Gastroenterology, Gastroenterology and Digestive Disorders | Cancer Science Conference on Fuzzy Information and Engineering | Medical Oncology Conference on Clinical Cancer Research and Immunology | Medical oncology Conference on Cancer Medical Research | Tumor Conference on Cancer Pharmacology and Research | Tumor Conference on Translational Research in Breast Cancer | Radiation oncology Conference on Radiography and Radiotherapy | Radiation oncology Conference on Nuclear Medicine and Radiotherapy | Chemotherapy Conference on Biomedical Sciences and Oncology | Carcinoma Conference on Health Monitoring, Medical Imaging and Radiation Oncology

Related Associations and Societies:

Protease inhibitors potentiate chemotherapy | Radiotherapy in Breast Cancer-Induced Bone Pain | Getting External Beam Radiation Therapy | Oncology Professional Organizations | American Society for Radiation Oncology | Getting External Beam Radiation Therapy | Association of frailty and chemotherapy | Association of proinflammatory cytokines and chemotherapy | Association of illness perception with chemotherapy | Protease inhibitors potentiate chemotherapy | Japanese Society of Medical Oncology | American Brain Tumour Association

Related Journals:

Track 4: Cancer Cachexia

The increasing prevalence of cancer and cachexia, especially due to the growing geriatric population, is driving the demand for advanced treatments and pharmaceuticals, which primarily drives the market growth. This is further supported by growing consumer awareness of the availability of new therapeutic agents to treat cancer cachexia.

In addition, changes in the patient’s propensity towards pharmacological, non-pharmacologic treatments and combination therapies to improve lean Body Mass (LBM) through clinical trials serve as another growth-promoting factor. Therefore, the widespread use of several appetite stimulants such as megestrol acetate, dexamethasone, and methylprednisolone to improve digestion also contributes to the market growth.

Sub Tracks:

· Progestogens.

· Corticosteroids

· Appetite Stimulators

· Weight Loss Stabilizers

Related Conferences:

Surgical oncology Conference on Oncology and Orthopedic Surgery | Surgical oncology Conference on Fuzzy Information and Engineering | Surgical oncology Conference on Advanced General Surgical Oncology and Surgery Types | Surgical oncology Conference on General Surgical Oncology and Surgery Types | Surgical oncology Conference on Advancements in General Surgical Oncology and Surgery Types | Cancer Conference on Prostate Cancer and Cancer Research | Cancer Conference on Cancer Medical Research | Cancer Science Conference on Cancer Science and Research | Cancer Science Conference on Veterinary Oncology, Diagnosis and Treatments | Medical oncology Conference on Novel Oncology Therapeutics | Medical oncology Conference on Biology and Medicine of Breast Cancer | Tumour Conference on Oncology Nursing Practice and Quality Cancer Care | Tumor Conference on Challenges and Controversies in Breast Cancer | Radiation oncology Conference on Nuclear Medicine and Radiotherapy

Related Association and Societies:

International Society of Geriatric Oncology | Asian Oncology Society | Journal of Surgical Oncology | American Association for Cancer Research | Association of Cancer With AIDS-Related Immunosuppression | Cancer Epidemiology, Biomarkers, and Prevention | Singapore Cancer Society | Breast Cancer Awareness Month: NHC Member American | Cardiovascular Disease and Breast Cancer | Getting External Beam Radiation Therapy | Radiotherapy in Breast Cancer Induced Bone Pain | Association of Comedication Quality With Chemotherapy | International Society of Antimicrobial Chemotherapy | Radiological Society of North America

Related Journals:

Journal of Surgical Oncology | International Journal of Cancer Science and Therapy | International Journal of Surgical Oncology | Journal of Surgical Oncology and Clinical Research | Journal of Cancer Science and Research | Journal of Cancer Science and Clinical Therapeutics | Journal of Cancer Science and Therapy | Journal of Cancer Science and Research Open Access | Journal of Cancer Science and Clinical Oncology | Journal of Cancer Clinical Research

Track 5: Oral Mucositis

The pathophysiology of surgical oncology through radiotherapy, chemotherapy, or radiotherapy and chemotherapy-induced oral mucositis is thought to result from a complex process beginning with tissue damage in a five-step model proposed by Sonis. The five stages of RT- and chemotherapy-induced OM occur sequentially, including initiation, signaling, amplification, ulceration, and healing. First, radiation or chemotherapy causes tissue damage leading to the death of basal epithelial cells and the generation of reactive oxygen species in cancer science.

Sub Tracks:

· Mucosal erythema

· Patchy ulceration

· Oral Mucositis Assessment Scale

· Oral Rinses

· Prognosis

Related Conferences:

Surgical oncology Conference on Surgical Oncology | Surgical oncology Conference on Advances in General Surgical Oncology and Surgery Types | Surgical oncology Conference on Clinical Oncology and Pharmacology | Surgical oncology Conference on Systems and Software Engineering | Cancer Conference on Lung Cancer Medical Research | Cancer Conference on Oncogenesis and Cancer Research | Cancer Science Conference on Cancer Health Disparities and Community-Based Research | Cancer Science Conference on Current Trends in Cancer Detection and Radiology Research | Medical oncology Conference on Oncology Cancer Practice and Administration of Chemotherapy | Medical oncology Conference on Surgical Gastroenterology and Surgical Oncology | Tumor Conference on Novel Oncology Therapeutics | Radiation oncology Conference on Radiography and Radiotherapy | Radiation oncology Conference on Diagnostic Imaging and Radiotherapy

Related Association and Societies:

Tampa Bay Surgical Oncology Society | International Society of Pediatric Surgical Oncology | American Association for Cancer Research | Cancer risk associated with chronic diseases | Cancer Epidemiology, Biomarkers & Prevention | Global Cancer Observatory | Skin cancer - American Academy of Dermatology | Canadian Association of Radiation Oncology | Cancer Patients Aid Association | Associations between palliative chemotherapy and adult cancer patients | Association of proinflammatory cytokines and chemotherapy | Association of Radiation Therapy With Risk of Adverse Events | German Cancer Research Centre | National Comprehensive Cancer Network

Related Journals:

Journal of Cancer Science and Research | International Journal of Cancer Science and Therapy | Journal of Surgical Oncology | Journal of Cancer Science and Research Open Access | Journal of Cancer Science and Clinical Oncology | Journal of Cancer Science and Therapy | Journal Home of Cancer Science and Research | Journal of Cancer Science and Clinical Therapeutics | Journal of Cancer Sciences | Journal of Cancer Science and Treatment

Track 6: Chemotherapy-Induced Thrombocytopenia

Patients treated for high-risk neuroblastoma and localized Ewing sarcoma with both high-dose cyclophosphamide and doxorubicin required the most platelet transfusions during the course of treatment, with an average of 13 and 13 transfusions, respectively. he was 9 times. Partly due to Chemotherapy Induced Thrombocytopenia, it was greatest in patients treated for high- and intermediate-risk rhabdomyosarcoma. Fifty-six percent of high-risk patients had an RDI decrease in the last two treatment cycles, and 69% of intermediate-risk patients had an RDI decrease in the last four treatment cycles.

Sub Tracks:

· Benzoates

· Hydrazine

· Pyrazoles

· Cisplatin

Related Conferences:

Surgical oncology Conference on Pediatric Surgery and Surgical Oncology | Surgical oncology Conference on Surgical Oncology | Surgical oncology Conference on Advanced General Surgical Oncology and Surgery Types | Cancer Conference on Current Research in Cancer Science and Immune Engineering | Cancer Conference on Cancer Health Disparities and Community-Based Research | Cancer Science Conference on Translational Research in Breast Cancer | Cancer Science Conference on Cancer Genomics Research | Medical oncology Conference on Cancer Pathology Research | Medical oncology Conference on Cell Biology, Immunology and Cancer Research | Tumor Conference on Biology and Medicine of Breast Cancer | Tumor Conference on Cancer Medical Research | Radiation oncology Conference on Applied Immunology and Oncology | Tumor Conference on Interventional Oncology | Radiation oncology Conference on Small Animal Oncology and Radiotherapy | Radiation oncology Conference on Radiography and Radiotherapy

Related Associations and Societies:

International Association for the Study of Lung Cancer | National and International Cancer Organizations | American Brain Tumor Association | German Cancer Research Centre | The Israeli Society for Clinical and Radiation Oncology | Radiotherapy in Breast Cancer-Induced Bone Pain | The Association of Chemotherapy and Radiotherapy | Associations Between Perceived Stress and Chemotherapy | Association of Radiation Therapy with Risk of Adverse Events | Society for Radiation Oncology Administrators | Medical Oncology Group of Australia

Related Journals:

Track 7: Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) is characterized by hyperuricemia, hyperkalemia, hypocalcemia, and hyperphosphatemia released after extensive cell death due to malignant tumors and is associated with normal homeostasis of the body. These electrolyte and metabolic disturbances can lead to toxic effects clinically, including renal failure, cardiac arrhythmias, stroke, and death. TLS occurs when tumor cells release their contents into the bloodstream. TLS is most common after systemic treatment of advanced hematologic malignancies but is rare in solid tumors and there are only a few cases reported in the literature.

Sub Tracks:

· Anorexia and fatigue.

· Dark urine decreased urine output

· Seizures or hallucinations.

· Palpitations.

· Hyperphosphatemia

Related Conferences:

Surgical oncology Conference on Applied Immunology and Oncology | Surgical oncology Conference on Challenges and Controversies in Breast Cancer | Surgical oncology Conference on Surgical Oncology | Cancer Conference on Digestive System Surgery and Surgical Oncology | Cancer Conference on Advances in General Surgical Oncology | Cancer Science Conference on Prostate Cancer and Cancer Research | Cancer Science Conference on Oncogenesis and Cancer Research | Medical oncology Conference on Cancer Health Disparities and Community-Based Research | Medical oncology Conference on Current Trends in Cancer Detection and Radiology Research | Tumour Conference on Cancer Research and Molecular Medicine | Tumor Conference on Blood Cancer Treatment and Research | Radiation oncology Conference on Breast Healthcare and Cancer Research | Carcinoma Conference on Veterinary Oncology, Diagnosis, and Treatments | Carcinoma Conference on Challenges and Controversies in Breast Cancer | Chemotherapy Conference on Women Oncology and Critical Care

Related Associations and Societies:

Cancer risk associated with chronic diseases | Cancer Research Institute - Advancing Immunotherapy | Japanese Cancer Association | Cancer Organizations and Support Groups | International Association for the Study of Lung Cancer | Global Cancer Observatory | Association of Cardiovascular Disease and Breast Cancer | Pediatric Radiation Oncology Society | Japanese Society for Radiation Oncology | Association between body composition and chemotherapy | Association of illness perception with chemotherapy | Association of Comedication Quality With Chemotherapy

Related Journals:

Track 8: Prostate Cancer

Many genetic mutations that are being studied as possible factors that increase the risk of prostate cancer are transmitted along the chromosome from both parents. Several recent studies have shown that certain types of mitochondrial DNA, inherited only from the mother, may increase the risk of prostate cancer in men. Some substances in tomatoes (lycopene) and soybeans (isoflavones) may help prevent prostate cancer.

Sub Tracks:

· Metastatic Castration-Resistant Prostate Cancer

· Enzalutamide Plus Androgen Deprivation Therapy

· Hematuria

· Androgen Receptor PROTAC Degrader

Related Conferences:

Surgical oncology Conference on Surgical Gastroenterology and Surgical Oncology | Surgical oncology Conference on Advances in General and Pediatric Surgical Oncology | Surgical oncology Conference on Recent Trends in General Surgical Oncology | Surgical oncology Conference on Artificial Neural Networks of Things | Cancer Conference on Surgical Gastroenterology and Surgical Oncology | Cancer Conference on Advanced General Surgical Oncology | Cancer Science Conference on Clinical Cancer Research and Immunology | Cancer Science Conference on Biomarkers in Cancer Research | Medical oncology Conference on Oncogenesis and Cancer Research | Medical oncology Conference on Blood Cancer Treatment and Research | Tumor Conference on Advancements in Cancer Detection and Radiology Research | Tumor Conference on Cancer Research and Therapy | Carcinoma Conference on Biomedical Sciences and Oncology | Radiation oncology Conference on Oncology Cancer Practice and Administration of Chemotherapy | Radiation oncology Conference on Breast Cancer | Chemotherapy Conference on Interventional Oncology

Related Associations and Societies:

International Society of Antimicrobial Chemotherapy | Associations between palliative chemotherapy and adult cancer patients | Association of Chemotherapy for Solid Tumors | Radiological Society of North America | Association of Radiation Therapy with Risk of Adverse Events | Society for Radiation Oncology Administrators | Hellenic Society of Medical Oncology | Florida Society of Clinical Oncology | The Association Between Cancer and Dementia | Association of proinflammatory cytokines and chemotherapy | Pediatric Radiation Oncology Society

Related Journals:

Journal of Cancer Science and Therapy | Journal Home of Cancer Science and Research | Journal of Cancer Science and Clinical Therapeutics | International Journal of Surgical Oncology | Journal of Surgical Oncology and Clinical Research | World Journal of Surgical Oncology | Journal of Cancer Sciences | Journal of Cancer Science and Research | International Journal of Cancer Science and Therapy | International Journal of Oncology Research

Track 9: Renal Cell Carcinoma

Approximately 30% of patients with renal cell carcinoma have metastases at diagnosis and 30-70% of tumors can recur after surgery. Targeted therapies such as tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, and VEGF monoclonal antibodies and immune checks to prolong progression-free survival (PFS) and overall survival (OS) in patients with advanced or metastatic disease Despite the promise of immunotherapies such as point inhibitors, RCC patients eventually succumb to inevitable drug resistance.

Sub Tracks:

· A lump on the side, abdomen, or lower back

· Blood in pee

· Back pain on one side

· Derived Drug Resistance

Related Conferences:

Surgical oncology Conference on Current Research in Cancer Science and Immune Engineering | Surgical oncology Conference on Challenges and Controversies in Breast Cancer | Surgical oncology Conference on Biology and Medicine of Breast Cancer | Cancer Conference on Gynecologic Surgery and Women Oncology | Cancer Conference on Oncology Nursing, Integrative Care and Pain Management | Cancer Conference on Translational Research in Breast Cancer | Cancer Science Conference on Cancer Research and Therapy | Medical oncology Conference on Challenges and Controversies in Breast Cancer | Medical oncology Conference on Biology and Medicine of Breast Cancer | Tumor Conference on Cancer Science and Radiology | Tumor Conference on Oncogenesis and Cancer Research | Radiation oncology Conference on Trends in General and Pediatric Surgical Oncology | Radiation oncology Conference on Radiography and Radiotherapy

Related Associations and Societies:

Related Journals:

Track 10: Cancer Metabolism

The rapid proliferation of liver cancer creates vulnerabilities in its energy production and cell aggregation processes that can be effectively exploited in new combination therapeutic strategies. hepatocytes, the main type of primary liver cancer (HCC) alters its metabolism to make it vulnerable to disruption of the supply of the key molecule arginine. They found that this arginine vulnerability was present in all his HCC cancers, regardless of the specific genetic mutation that caused them.

Sub Tracks:

· Glucose

· Amino acids

· Cancer’s messaging system

· Anabolism and Catabolism

Related Conferences:

Surgical oncology Conference on Small Animal Oncology and Radiotherapy | Surgical oncology Conference on Cell Biology, Immunology and Cancer Research | Surgical oncology Conference on Pediatric Surgery and Surgical Oncology | Surgical oncology Conference on Labour Economics and Industrial Relations | Cancer Conference on Surgical Oncology | Cancer Conference on Fuzzy Information and Engineering | Cancer Science Conference on Recent Trends in Cancer Detection and Radiology Research | Cancer Science Conference on Advancements in Cancer Detection and Radiology Research | Medical oncology Conference on Clinical Cancer Research and Immunology | Medical oncology Conference on Cell Biology, Immunology and Cancer Research | Tumor Conference on Oncology Nursing Practice and Quality Cancer Care | Tumor Conference on Medical Biology and Oncology | Radiation oncology Conference on Oncology Nursing, Integrative Care and Pain Management | Chemotherapy Conference on Cancer Research and Therapy | Carcinoma Conference on Cancer Research and Molecular Medicine | Radiation oncology Conference on Radiography and Radiotherapy

Related Associations and Societies:

Related Journals:

Track 11: Computational Oncology

Mathematical modeling in computational oncology can be used to study the pharmacokinetic and pharmacodynamic relationships of available anticancer agents to improve their cancer treatment. Achieving the optimal balance between toxicity and efficacy has become an increasingly complex task as the number of drug-deliverable molecular targets and possible drug combinations continues to grow as cancer. As a result, standard empirical approaches for optimizing patient drug dosing and planning are currently of limited use. Mathematical modeling can greatly advance this practice by improving the rationalization of treatment strategies in computational oncology.

Sub Tracks:

· Cellular Pathway Databases.

· Microarray Analysis.

· Cellular Imaging and Drug Development.

· Cancer Metabolism and Systems Toxicology

Related Conferences:

Surgical oncology Conference on Pediatric Surgery and Surgical Oncology | Surgical oncology Conference on Advances in General and Pediatric Surgical Oncology | Surgical oncology Conference on Recent Trends in General Surgical Oncology | Surgical oncology Conference on Advanced General Surgical Oncology and Surgery Types | Cancer Conference on Advanced General Surgical Oncology | Cancer Conference on Cancer Research and Therapy | Cancer Conference on Cancer Health Disparities and Community-Based Research | Cancer Science Conference on Women’s Health and Breast Cancer | Cancer Science Conference on Clinical Cancer Research and Immunology | Medical oncology Conference on Cancer Health Disparities and Community-Based Research | Medical oncology Conference on Biomarkers in Cancer Research | Tumor Conference on Biology and Medicine of Breast Cancer | Tumor Conference on Veterinary Oncology, Diagnosis and Treatments | Carcinoma Conference on Medical Imaging and Radiotherapy | Radiation oncology Conference on Intraoperative Radiotherapy

Related Associations and Societies:

Global Cancer Observatory | American Society of Clinical Oncology | National Comprehensive Cancer Network | International Association for the Study of Lung Cancer | Cancer Epidemiology, Biomarkers and Prevention | Comparison of Cancer Burden and Non-profit Organization | Integrative Cancer Science and Therapeutics | Association of Radiation Therapy with Risk of Adverse Events | Radiological Society of North America | The Association of Chemotherapy and Radiotherapy | International Society of Antimicrobial Chemotherapy | Canadian Association of Radiation Oncology | International Society of Geriatric Oncology

Related Journals:

Track 12: Colon Cancer

Colorectal cancer needs better early detection and treatment options. Incidence is increasing in the young population. Circulating tumor DNA provides a way to select patients for adjuvant chemotherapy. Immunotherapy is an option for patients with mismatch repair protein deficiency. However, efficacy outside this patient population remains a challenge. Targeted therapies such as BRAF inhibitors are an option for poor prognosis patients for whom cytotoxic chemotherapy is not very effective in colon cancer.

Sub Tracks:

· Managing Metastatic Disease

· Fecal occult blood test

· Recurrent Colon Cancer

· Flexible sigmoidoscopy

Related Conferences:

Surgical oncology Conference on Gastroenterology, Gastroenterology and Digestive Disorders | Surgical oncology Conference on Advances in General Surgical Oncology and Surgery Types | Surgical oncology Conference on Recent Trends in General Surgical Oncology | Surgical oncology Conference on Musical Research | Cancer Conference on Artificial Neural Networks of Things | Cancer Science Conference on Clinical Oncology and Pharmacology | Cancer Science Conference on Recent Trends in General Surgical Oncology and Surgery Types | Medical oncology Conference on Digestive System Surgery and Surgical Oncology | Medical oncology Conference on Prostate Cancer and Cancer Research | Tumor Conference on Cancer Science and Radiology | Tumor Conference on Cancer Genomics Research | Radiation oncology Conference on Cancer Health Disparities and Community-Based Research | Chemotherapy Oncology Conference on Blood Cancer Treatment and Research | Radiation oncology Conference on Oncology and Orthopedic Surgery

Related Associations and Societies:

American Society of Clinical Oncology | Oncology Professional Organizations | Canadian Association of Radiation Oncology | Association of Comedication Quality with Chemotherapy | Association of Chemotherapy for Solid Tumors | International Society of Geriatric Oncology | Florida Society of Clinical Oncology | The Israeli Society for Clinical and Radiation Oncology | Association of illness perception with chemotherapy | Cancer, and food - Better Health Channel | Association of Cardiovascular Disease and Breast Cancer | Breast Cancer Awareness Month: NHC Member American

Related Journals:

Track 13: Esthesia neuroblastoma

Esthesia neuroblastoma presents with numerous chromosomal aberrations, deletions, and gains, but no consistent pattern. In one study, specific deletions of chromosome 11 and gains of chromosome 1p were associated with metastasis and poor prognosis in cancer science. Gains are more common than losses, and high-stage esthetic neuroblastoma shows more changes than low-stage tumors. Increases in 20q and 13q may be important for the progression of this neoplasm. These regions may harbor genes functionally related to esthetic neuroblastoma. PTCH1, GL/1, and GL/2 were detected in 70%, 70%, and 65% of human esthetic neuroblastoma specimens, respectively, implicating the SHH signaling pathway in the pathogenesis of this neoplasm. suggesting that it is possible.

Sub Tracks:

· Sino nasal malignant melanoma

· Nose bleeding.

· Extramedullary plasmacytoma

· Difficult to breathe

Related Conferences:

Surgical oncology Conference on Medical Oncology and Molecular Medicine | Chemotherapy Oncology Conference on Oncology Cancer Practice and Administration of Chemotherapy | Surgical oncology Conference on Current Trends in Cancer Detection and Radiology Research | Surgical oncology Conference on Cancer Health Disparities and Community-Based Research | Cancer Science Conference on Gynecologic Surgery and Women Oncology | Medical oncology Conference on Veterinary Oncology, Diagnosis and Treatments | Medical oncology Conference on Surgical Gastroenterology and Surgical Oncology | Tumor Conference on Women Oncology and Critical Care | Carcinoma Conference on Oncology and Orthopedic Surgery | Radiation oncology Conference on Radiotherapy in Cancer | Radiation oncology Conference on Medical Imaging and Radiotherapy | Carcinoma Conference on Nuclear Medicine and Radiotherapy

Related Associations and Societies:

Association of Radiation Therapy with Risk of Adverse Events | International Society of Geriatric Oncology | The Cancer Association of South Africa | Association of Cardiovascular Disease and Breast Cancer | Society of Gynecologic Oncology | Society for Radiation Oncology Administrators | Association of frailty and chemotherapy | The British Society for Antimicrobial Chemotherapy | Florida Society of Clinical Oncology | Breast Cancer Awareness Month: NHC Member American | International Society of Pediatric Surgical Oncology | European Journal of Surgical Oncology

Related Journals:

Track 14: Craniopharyngioma

Although classified as a grade I tumor by the World Health Organization, craniopharyngiomas are highly susceptible due to their close involvement and massive impact on surrounding vital structures, including the hypothalamus, pituitary gland, and optic chiasm, and their propensity to Even after successful relapse, it can cause significant morbidity. treatment. Many extensive and detailed studies have been conducted on craniopharyngioma. However, due to benign histology, epidemiological rarity compared to malignant tumors, and the absence of tumors, two major subtypes of craniopharyngioma (adamantinoma and squamous) have been identified in the last century. Research on the genetic and molecular basis of papillae) has been limited. Research platforms and technical conditions relevant to these lesions.

Sub Tracks:

· Treatment for papillary craniopharyngioma.

· Experimental Research

· Mice model

· Clinical trials in craniopharyngioma

Related Conferences:

Surgical oncology Conference on Cancer Immunotherapy and Radiotherapy | Surgical oncology Conference on Intraoperative Radiotherapy | Surgical oncology Conference on Health Monitoring, Medical Imaging and Radiation Oncology | Cancer Conference on Medical Oncology and Molecular Medicine | Cancer Science Conference on Small Animal Oncology and Radiotherapy | Cancer Science Conference on Cell Biology, Immunology and Cancer Research | Medical oncology Conference on Lung Cancer Medical Research | Medical oncology Conference on Cancer Medical Research | Tumor Conference on Cancer Research and Therapy | Tumor Conference on Cancer Pathology Research | Radiation oncology Conference on Challenges and Controversies in Breast Cancer | Carcinoma Conference on Novel Oncology Therapeutics | Radiation oncology Conference on Nuclear Medicine, Imaging and Radiotherapy

Related Associations and Societies:

National and International Cancer Organizations | Cancer risk associated with chronic diseases | Indian Society of Medical and Pediatric Oncology | Association of Chemotherapy for Solid Tumors | The Israeli Society for Clinical and Radiation Oncology | Association of proinflammatory cytokines and chemotherapy | Radiotherapy in Breast Cancer-Induced Bone Pain | Oncology Nursing Society | Tampa Bay Surgical Oncology Society | European Journal of Surgical Oncology | Society of Surgical Oncology-American Society for Radiation

Related Journals:

Track 15: Chronic Lymphocytic Leukemia

Clinical staging systems use physical examination and blood count results to provide prognostic information. Various biological and genetic markers provide additional prognostic information. Short-arm deletions of chromosome 17 and or mutations in the TP53 gene predict resistance to chemoimmunotherapy and shortened time to progression with most targeted therapies in surgical oncology. The chronic lymphocytic leukemia international prognostic index integrates tumor genetic, biological, and clinical variables to identify different risk groups of CLL patients in oncology.

Sub Tracks:

· Cell diagnosis

· Monoclonal antibodies

· Immunophenotyping

· Epigenome

Related Conferences:

Surgical oncology Conference on Surgical Gastroenterology and Surgical Oncology | Surgical oncology Conference on General and Pediatric Surgical Oncology | Surgical oncology Conference on Gastroenterology, Gastroenterology and Digestive Disorders | Surgical oncology Conference on Oncogenesis and Cancer Research | Surgical oncology Conference on Current Research in Cancer Science and Immune Engineering | Cancer oncology Conference on Challenges and Controversies in Breast Cancer | Cancer Conference on Diabetes and Cancer Research | Cancer Science Conference on Male Breast Cancer | Medical oncology Conference on Medical Imaging and Radiotherapy | Radiation oncology Conference on Nuclear Medicine and Radiotherapy | Radiation oncology Conference on Radiotherapy in Cancer | Chemotherapy Oncology Conference on Gynecologic Surgery and Women Oncology

Related Associations and Societies:

American Society of Clinical Oncology | Asian Oncology Society | National Comprehensive Cancer Network | Association of Cancer With AIDS-Related Immunosuppression | Cancer, and food - Better Health Channel | German Cancer Research Centre | The Association Between Cancer and Dementia | Hellenic Society of Medical Oncology | The Israeli Society for Clinical and Radiation Oncology | Association of illness perception with chemotherapy | Protease inhibitors potentiate chemotherapy | Associations between palliative chemotherapy and adult cancer patients | Canadian Association of Radiation Oncology | Society of Gynecologic Oncology

Related Journals:

Market Analysis & About Conference

The global cancer therapeutics market size is projected to grow by $223.21 billion in 2022, at a compound annual growth rate (CAGR) of 11.6%. The market growth is mainly due to companies reorganizing their operations and recovering from the impact of COVID-19. The cancer drug market is expected to reach US$540.6 billion in 2026, at a CAGR of 24.8%.

The global market for oncology information systems was estimated to be worth USD 2.4 billion in 2021, and it is forecast to grow at a 7.8% CAGR from 2022 to 2030. The market is expected to increase as a result of the massive rise of healthcare IT, the rising incidence of cancer around the world, rising development costs for cancer treatments, care, and the expanding use of OIS products by healthcare organizations. According to percancer.org, there were more than 1.9 million new cancer cases detected in the U.S. alone in 2021. Numerous cutting-edge technologies are being created that have the potential to change the treatment plan.

During the forecasted years, the surgical oncology category is also predicted to have significant expansion. Over the years, cancer care has advanced significantly. The majority of solid tumors are no longer treated surgically; instead, the ideal method of care is a mix of surgery and multi-modal therapies with a primary focus on radiation, targeted molecular therapies, and chemotherapy. Some operations can be carried out in highly specialized healthcare facilities, including sarcoma surgery, isolated limb perfusion, laparoscopic cancer surgery, and chemotherapy and radiation therapy surgery. Therefore, it is estimated that the rising difficulty of surgical treatments for solid malignancies will propel market expansion.

The oncology drug market consists of the sale of oncology drugs and related services by companies (organizations, sole proprietorships, and partnerships) that manufacture oncology drugs used in the diagnosis and treatment of all types of cancer. It has been. This industry includes facilities that manufacture drugs used in chemotherapy, surgery, and radiation therapy to treat pancreatic, breast, ovarian, brain, and various other cancers.

Recent advancements in Breast Cancer:

No benefit from adjuvant ibandronate in postmenopausal women with breast cancer:

In a randomized trial, adjuvant bisphosphonates improved disease-free survival (DFS) in postmenopausal women at moderate or higher risk of breast cancer recurrence. In a recent randomized study of over 1,100 postmenopausal women, oral ibandronate 50 mg daily did not improve her DFS compared with a placebo. A previous head-to-head study in both premenopausal and postmenopausal women found similar DFS results with clodronate, ibandronate, and zoledronic acid, but this study is currently limited to postmenopausal women. was the second study not to report a benefit of DFS with ibandronate versus placebo. Zoledronic acid or clodronate is recommended for patients for whom bisphosphonates are indicated as adjuvant therapy for breast cancer, and ibandronate is considered a less preferred alternative.

Vaginal estrogenic remedy in sufferers with a record of breast cancer:

Low-dose intravaginal estrogen is an effective treatment for moderate to severe symptoms of the menopausal genitourinary syndrome (GSM) unresponsive to non-hormonal therapies (vaginal moisturizers, lubricants), but in breast cancer patients Its safety is unknown. In a study of postmenopausal patients with a history of early-stage estrogen-positive breast cancer and treated with an aromatase inhibitor (AI), patients who used vaginal estrogen after breast cancer diagnosis were at an increased risk of breast cancer recurrence compared with non-users. was expensive.

Radiation enhances ductal carcinoma in situ:

The use of bedside radiation enhancement reduces recurrence in patients undergoing whole-breast radiotherapy (WBRT) for early-stage invasive breast cancer, but its role in ductal carcinoma in situ (DCIS) is less pronounced. Not clear. In a randomized study of more than 1600 DCIS patients with at least one risk characteristic, patients assigned to radiation enhancement had a local recurrence rate of 97% over 5 years, compared with a 93% in the no group (hazard ratio 0.47). For most women undergoing her WBRT for early-stage breast cancer, including DCIS, we recommend intensifying radiation therapy at the tumor bed to reduce the risk of local recurrence. (See Adjuvant Radiation Therapy for Women with Newly Diagnosed Nonmetastatic Breast Cancer, section "Tumor Bed RT Augmentation.")

Combination of pembrolizumab and chemotherapy in PD-L1-positive advanced triple-negative breast cancer:

The use of immune checkpoint inhibitors in combination with chemotherapy is being evaluated in patients with advanced PD-L1-positive triple-negative breast cancer (TNBC). In a randomized study, pembrolizumab plus placebo to chemotherapy improved overall survival in patients with advanced TNBC, and a composite positive score (CPS) of 10 or higher for PD-L1 expression was shown (23 vs. 16 months). Based on these data, we propose adding pembrolizumab to chemotherapy in patients with Cancer with advanced PD-L1-positive TNBC with CPS? 10.

Best Global University for Oncology:

· Harvard University.

· Johns Hopkins University.

· Cornell University.

· University of California--San Francisco.

· University of Toronto.

· University of California--Los Angeles.

· Yale University.

· Vanderbilt University.

Global Cancer Diagnostics Market Dynamics:

· The increasing number of private diagnostic techniques.

· Cancer screening recommendations.

· Increased Acceptance of Refurbished Imaging Systems.

· The biggest market share for cancer diagnostics was maintained by the technology

sector.

· The market for cancer diagnostics was dominated by North America

Market by Cancer Diagnostics:

· Imaging

· Biopsy

· Liquid Biopsy

· Tumor Biomarkers test

· In Situ Hybridization

Market by Treatment:

· Chemotherapy

· Targeted therapy

· Immunotherapy

· Hormonal therapy

· Others

Some of the key players in the global oncology market are:

· Egerton Pharmaceutical Co., Ltd.

· AbbVie Inc.

· Ability Pharma

· Acadia Pharmaceuticals, Inc.

· Amgen

· Takeda Oncology

· Athrun Pharmaceuticals Limited Aspen Pharmacare Holdings Limited.

· AstraZeneca

· Athenex Co., Ltd.

Past Conference Report

We would like to be grateful to all our outstanding keynote speakers, conference participants, students, associations, media partners, exhibitors, and attendees for making Surgical Oncology 2021 a successful, memorable, and magnificent event.

AAC established the 20^th Annual Summit on Surgical Oncology on May 19, 2021, as a Webinar based on the theme Distinctive Innovations in Surgical Oncology.

The Editorial Board Members of major international journals, as well as leading academic scientists, researchers, research scholars, students, and leaders in the fields of surgical oncology.

The surgical oncology 2021 Conference was recognized by the presence of young and outstanding academics, business representatives, and talented student communities from over 20 countries, all of whom contributed to the success of the event. Various presentations on contemporary retroviral research were highlighted at the conference.

Surgical Oncology 2021 included a diverse group of world-class speakers who shared their knowledge and confabulated on a variety of topics in the domains of surgical oncology.

The event was organized into several sessions, with discussions taking place on the following important scientific tracks:

·Surgical Oncology

·Palliative Care in Surgical Oncology

·Gynecologic Oncology

·Surgical Oncology Test and Surgical Procedures

·Breast Cancer

The conference started out with a welcoming remark and a series of talks by Keynote forum members, as well as a special session with an exhibitor representative with their tremendous eloquence, With plenary lectures from experts from various universities and organizations, the event enlightened various fields of surgical oncology.

Honourable Guest, Keynote, and Plenary:

·Michael Retsky| University College London | UK

·Jayashree Joshi| Kasturba Research Society| India

·Ashwini.Nerkar. Rajbhoj| DY Patil dental school | India

·Sara Maria Moreira Lima Verde | Ceara Cancer Institute | Brazil

·Auj-E Taqaddas| Research Wormhole | UK

·Ana Golez| General and Teaching Hospital Celje | Slovenia

·Vinay Gaikwad | Paras Hospital | India

·Soldano Ferrone | Massachusetts General Hospital| Massachusetts

·Yasaman Herandi | Tehran University of Medical Science | Iran

·Daniela Darmasceno | University of Salamanca and Institute of Biomedical Research of Salamanca | Spain

·Veronica Salais | Hospital General de Ciudad Juarez| Mexico

·Clevio Joao Baptista Desouza | Dr D.Y. Patil Medical College| India

Hagar Hassan Fahi | October University for Modern Sciences and Arts | Egypt

The organizing committee, keynote speakers, delegate experts, company representatives, and other distinguished persons who contributed to the success of this event are honoured by AAC. The organizing committee of surgical oncology 2021 congratulates the awards on their excellent achievements in the field of Surgical Oncology, thanks all participants for their presentations, and wishes them luck in their future activities.

Following the success of Surgical Oncology 2021, AAC proudly announces the start of the "21^st Annual Summit on Surgical Oncology and Cancer Science" which will be held on April 03-05, 2023 with the theme of “Pioneering the advancements in Surgical Oncology and Cancer Science”.